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ABSTRACT 
Background: Long-term outcomes of antiretroviral therapy (ART) in resource-poor 
settings in Haiti are unknown. Understanding the psychosocial and contextual factors 
that enable patients living with HIV/AIDS to survive at least 10 years after the initiation 
of ART is necessary. Given Haiti’s unique and fragile political and economic 
infrastructure, we describe the 10-year outcomes, characteristics of the first cohort of 
patients receiving ART in Haiti, and the experience of the 10-year survivors in the 
following chapters. 
 
Methods: Data from 910 patients, age ≥ 13 years, who initiated ART from 2003-2004 
were included. Lost-to follow-up (LTF) was defined as no clinic/pharmacy visit within 
180 days of the date of censor. Kaplan Meier, contact tracing with inverse probability 
weighting, and multiple imputation methods were used to estimate survival.  Cox 
modeling and logistic regression were used to identify characteristics associated with 
survival. Additionally, individual audiotaped in-depth interviews that lasted 45 to 60 
minutes using a semi-structured open-ended format were conducted with 25 participants 
who survived at least 10 years with AIDS in between January 2015 and August 2015.  
Grounded theory approach was used for data collection and analysis.  Each interview 
was then transcribed verbatim and back-translated from Creole to English. Questions 
focused on understanding how participants survived in the midst of challenges faced by 
the 10-year survivors since starting ART, coping strategies used to overcome those 
challenges, accomplishments that they made during those 10 years, and their hopes.   
  
Results: Among 910 adults who initiated ART, 55% were female, median age was 38 
years, and median CD4+ was 131 cells/uL (IQR 57-212). Ten years after ART initiation, 
  
53% were alive, 27% dead, 12% were LTF, and 8% transferred care. Ten-year survival 
estimates ranged from 63–71%.  Forty-two percent of deaths occurred in the first 6 
months;  characteristics associated with early death were being male, age > 50 years, 
low weight, WHO Stage III/IV, and baseline TB. Characteristics associated with death 
after 6 months were age > 50 years, income < $1 per day, low weight, and low 
adherence. Among 10-year survivors, 58% were female, median age was 49 years 
(IQR43-55), and median CD4+ was 541 cells/uL.  Seventy-three percent remained on 
first-line therapy and 38% had a chronic non-communicable disease. We integrated our 
core findings into an explanatory framework. The 25 participants described stressors 
aside from HIV, including poverty, sociopolitical challenges and stigmatization that are 
counterbalanced with positive outlook and the fact of having a goal. Psychosocial 
factors like caring for one’s child, spirituality and faith, the role of providers and 
adherence to antiretroviral helped them to look past the disease and have another 
meaning to theirs lives in order to survive the 10 years of ART. 
 
Conclusion: The 10-year survival of patients with AIDS receiving ART in Haiti is 
approximately 70%, which demonstrates the long-term sustainability of international 
efforts to provide ART in resource-poor settings. Aside the devastating health impacts 
of HIV itself, there was an underlying current of resilience, hope, and the desire to live. 
As described in the second study, women with children wanted to work and support 
their children’s education. This study provides a portrait of Haiti that is not defined by 
death or hopelessness.     
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ABSTRACT 
Background: Long-term outcomes of antiretroviral therapy (ART) in resource-poor 
settings are unknown. We describe the 10-year outcomes and characteristics of the 
first cohort of patients receiving ART in Haiti.  
 
Methods: Data from 910 patients, age ≥ 13 years, who initiated ART from 2003-2004 
were included. Lost-to follow-up (LTF) was defined as no clinic/pharmacy visits 
within 180 days of the date of censor. Kaplan Meier, contact tracing with inverse 
probability weighting, and multiple imputation methods were used to estimate survival.  
Cox modeling and logistic regression were used to identify characteristics associated 
with survival. 
 
Results: Among 910 adults who initiated ART, 55% were female, median age was 38 
years, and median CD4+ was 131 cells/uL (IQR 57-212). Ten years after ART 
initiation, 53% were alive, 27% dead, 12% were LTF, and 8% transferred care. Ten-
year survival estimates ranged from 63–71%.  Forty-two percent of deaths occurred in 
the first 6 months;  characteristics associated with early death were being male, age > 
50 years, low weight, WHO Stage III/IV, and baseline TB. Characteristics associated 
with death after 6 months were age > 50 years, income < $1 per day, low weight, and 
low adherence. Among 10-year survivors, 58% were female, median age was 49 years 
(IQR43-55), and median CD4+ was 541 cells/uL.  Seventy-three percent remained on 
first-line therapy and 38% had a chronic non-communicable disease. 
 
Conclusion: The 10-year survival of patients with AIDS receiving ART in Haiti is 
approximately 70%, which demonstrates the long-term sustainability of international 
efforts to provide ART in resource-poor settings.  
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INTRODUCTION 
Over the past decade, nearly 12 million HIV infected persons have initiated 
antiretroviral therapy (ART) in resource-poor countries (1, 2).  This extraordinary 
international effort has led to a decrease in HIV-related deaths from 2.3 million in 
2005 to 1.6 million in 2012, and a decrease of HIV transmission at the population 
level (1). Scale-up of ART has also dramatically strengthened families and 
communities through increased school attendance, increased worker productivity, and 
improved family income status (3-6).   
 The long-term, 10-year survival of HIV-infected persons receiving ART in 
resource-poor countries remains uncertain.  Long-term survival estimates are 
important to evaluate the impact and sustainability of HIV programs, identify the 
health needs of patients on lifelong treatment, and adapt HIV programs to meet the 
needs of this aging population.  
 The clinic of Haitian Study Group for Kaposi's Sarcoma and Opportunistic 
Infections (GHESKIO) was established in 1983, is the first HIV/AIDS clinic in Latin 
America and the Caribbean (7).  In 2003, Haiti had an adult HIV prevalence of 6%, 
which was the highest in the Western Hemisphere (8).  From 2003 to 2004, GHESKIO 
obtained international funding and was one of the first organizations to provide free 
ART to all eligible patients in a resource-poor setting (7).  The objectives of this 
analysis are to determine the 10-year survival of the first cohort of patients to receive 
ART in Haiti, identify predictors associated with survival, and detail the 
characteristics of the 10-year survivors. 
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METHODS 
Study Site and Population:  
GHESKIO is located in downtown Port-au-Prince and serves a catchment population 
of approximately 3 million persons, the majority of whom live under the national 
extreme poverty line of 1.24 dollar per day (9).  The study population is the first 
cohort of 910 individuals, age 13 years or older, who initiated ART at GHESKIO 
between March 2003 and April 2004.  Details and short-term outcomes of this cohort 
have been previously described (7, 10).  
 
GHESKIO’s ART Program:  
The GHESKIO clinic staff who initiated and cared for the cohort of patients during the 
study period (2003-2014) was compromised of a multidisciplinary team of physicians, 
nurses, a social worker, peer counselors and community health workers.  Patients were 
routinely seen in the clinic by a physician every 2 weeks during the first 3 months of 
treatment and by a nurse monthly thereafter.  Eligibility criteria for ART in 2003-2004 
followed WHO guidelines and included an AIDS-defining illness or a CD4 count < 
200 cells/uL(11).  In 2006, eligibility criteria for ART changed to a CD4 count < 350 
cells/uL and in 2010 again changed to a CD4 count < 500 cells/uL in 2010(12, 13).  
From 2003 to 2004, the first-line ART regimen was zidovudine, lamivudine, and 
efavirenz or nevirapine, with single-drug substitutions permitted as outlined by WHO.  
Tenofovir-based regimens became first-line treatment in 2010.  Second-line regimens 
(lopinavir and atazanavir) were available in 2004. Medications were dispensed 
monthly directly to the patients. CD4 counts were performed every 6 months and viral 
load was not routinely measured.  Retention in care and adherence to therapy was 
encouraged by peer counseling by people with AIDS, transport support, home visits, 
and social support programs.  Patients who missed a clinic appointment were traced in 
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the community by field workers, for up to 6 months from the date of the missed 
appointment to ascertain vital status and return patients to care. Since 2003, over 
10,000 patients have been initiated on ART at GHESKIO.   
 
Clinical Measurements and Outcomes: 
Clinical measurements at the time of ART initiation included body weight, CD4 
count, co-infection with tuberculosis, and WHO staging. Demographic characteristics 
included age, sex, income (dichotomized at $1/day), marital status, residence, referral 
type for HIV care, and education.   
The primary outcome of this analysis was survival at 10 years after initiation of 
ART. Date of death and transfer were documented in the medical record.  A patient 
was categorized as lost to follow-up (LTF) if there was no clinic or pharmacy visit 
within 180 days of the last clinic visit or the 10-year anniversary date of ART 
initiation.  We examined survival estimates both after the first 6 months of ART and at 
10 years based on studies reporting high rates of early mortality immediately after 
ART initiation due to opportunistic infections (10, 14-17).  
Adherence, measured at 6 months after ART initiation, was defined as the 
proportion of pills prescribed that patients collected from the pharmacy (18). 
Diagnosis of tuberculosis followed the definition of the American Thoracic Society 
and has been used in our prior reports (19-23). Diagnosis of a chronic non-
communicable disease was assessed by identifying a clinical diagnosis in the medical 
or pharmacy record of cardiovascular disease (e.g., hypertension, coronary artery 
disease, or hyperlipidemia), chronic lung disease (e.g, asthma and chronic obstructive 
lung disease), or diabetes. 
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Contact Tracing of Patients Lost to Follow-up: 
GHESKIO staff routinely traced patients who missed appointments throughout the 
study period.  In 2013-2014, staff attempted to contact all patients who had been 
categorized as LTF at 10 years after initiating ART, the end of the study period.  
  
Events in Haiti Over the 10-Year Follow Up Period:  
During the 10-year study period, there were continuous political, socioeconomic and 
natural catastrophes in Haiti (24).  In 2004, there was a political coup resulting in UN 
military occupation of the country with a series of disputed political elections.  A 
historic earthquake occurred in Port-au-Prince in January 2010, which killed over 
200,000 and displaced more than 3 million (25).  The largest Cholera epidemic in 
modern history hit in October 2010 and claimed an additional 8,500 lives (26).  
 
Statistical Analysis: 
We used three methods to assess survival at 6 months and 10 years of follow-up: 1) 
Kaplan-Meier survival analysis methods, 2) inverse-probability weighting survival 
analysis, and 3) logistic regression with the use of multiple imputation with chained 
equations.  Each method accounts for LTF differently given the status of LTF is not a 
patient outcome but rather a mixed category of undocumented deaths, undocumented 
or silent transfers, and patients who are alive but disengaged from care (27-29).  
Standard Kaplan Meier survival methods censor patients who are LTF, which assumes 
that being LTF is not associated with survival.  Patients who were LTF or transferred 
were censored at the date of last clinic date of date of transfer.  Survival analysis with 
inverse probability weighting assigns a weight equal to the inverse probability of vital 
status ascertainment for traced participants (30). Applying these weights, participants 
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traced are weighted to represent the population of all patients who were lost to follow-
up.  The weighting assumes that individuals successfully traced at 10 years have the 
same probability of death as those LTF but not traced throughout the study period.  
This method assumes that the sample with successful tracing is representative of those 
LTF who were not successfully traced. The third method is logistic regression with the 
use of multiple imputation with chained equations (20 imputations) to assign vital 
status at 6 months and 10 years (31).  Multiple imputation techniques assume that 
missing data is missing at random and that, conditioned on the covariates used to 
impute outcome status, individuals who are LTF have the same risk of an outcome (in 
this case death) as individuals not LTF.  Using this method, vital status was imputed 
among participants categorized as LTF or transferred. 
Characteristics associated early and late death were generated using cox 
proportional hazard models and logistic regression.  Missing data for CD4+ count, 
weight, and adherence at 6 months were imputed. Variables associated with mortality 
in previous publications or in our clinical experience were included in the initial 
model.  We used STATA statistical software (Version 13.0, College Station, Tx) for 
all analyses.  
 
Ethics: 
The institutional review boards at GHESKIO and at Weill Medical College of Cornell 
University approved this study. 
 
RESULTS 
Patient Characteristics at ART initiation: 
Table 1.1 describes the characteristics of the 910 patients who were initiated on ART 
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in 2003–2004.  Fifty-five percent were female with a median age of 38 years (IQR 33-
45).  Approximately half of the cohort lived in extreme poverty earning < $1 per day, 
and had no or only primary-level schooling.  All patients had AIDS at the time of ART 
initiation: median CD4 count was 131 cells/uL (IQR 51-212) with 20% having a 
CD4+ < 50 cells/uL, and 39% with advanced WHO Stage III or IV symptoms.  
 
Table 1.1 Characteristics of Patients at Time of ART Initiation in 2003–2004 (N=910) 
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Patient outcomes:  
Contact tracing of 161 participants who were categorized as LTF at the end of the 10-
year study period found 39 patients to be alive and re-engaged in care, 11 dead, and 
the remaining 111 were classified as lost.  
Six Months:  At 6 months after ART initiation, 779 (86%) of the cohort was alive, 103 
(11%) were dead, 27 (3%) were lost and one patient transferred (Figure 1.1). 
Ten Years:  At 10 years after ART initiation, 482 (53%) were known alive, 246 (27%) 
were dead, 111 (12%) were lost, and 71 (8%) had transferred.   
The mortality rate in the first 6 months was 25 deaths per 100 patient years (PY).  
Over the next 9.5 years the mortality rate was 2.5 deaths per 100 PY.   Mortality rates 
did not significantly differ in calendar year 2010, following the earthquake as 
compared to other years (1 death/100 PY in 2009, 2 deaths/100 PY in 2010 and 1.5 
deaths/100 PY in 2011).  
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Figure 1.1 Outcomes over 10 years of follow-up among 910 patients who initiated 
ART between 2003–2004 in Haiti
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Ten-Year Survival Estimates:  Three methods were used to estimate survival by 
accounting for death among patients categorized as lost to follow up. Kaplan Meier 
survival analyses estimated that 71% (95% CI 68%–74%) were alive at 10 years. 
Inverse probability weighting estimated 63% survival (95% CI 59%–67%), and 
multiple imputation methods estimated 67% survival at 10 years (95% CI 64%–71%) 
(Table 1.2).  
 
Table 1.2 10-year Survival Estimates using three survival analysis methods for 910 
patients who initiated ART between 2003-2004 in Haiti 
Tuberculosis: Eighty patients (9%) had tuberculosis at time of ART initiation.  A total 
of 134 patients (15%) developed tuberculosis over the study period with TB incidence 
of 14.5 cases/100 PY in the first 6 months and 1.3 cases/100 PY from 6 months to 10 
years.  
50%
60%
70%
80%
Kaplan-Meier Inverse Probability
Weighting
Multiple Imputation
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METHOD ESTIMATED ALIVE, % (95% CI)
Kaplan–Meier 71% (68, 74)
Inverse Probability Weighting 63% (59, 67)
Multiple Imputation 67 (64, 71)
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Adherence:  Among patients who survived to 6 months, the median adherence was 
97% (IQR 88%-100%).  Sixty-nine percent had an adherence greater than 90%, 11% 
had adherence 80-80%, 6% had adherence 70-79%, and 15% had adherence less than 
70%.    
Predictors of Survival:  
The characteristics predictive of 6 month mortality were predominately biomedical 
factors including low weight, WHO Stage III/IV symptoms and baseline TB.  Other 
predictors include being male and age > 50 years (Table 1.3).  Characteristics 
associated with death after 6 months through 10 years include age > 50 years and 
lowest quartile weight for sex, with the addition of sociodemographic and behavioral 
characteristics of extreme poverty and lowest quartile of adherence (Table 1.3).  
Using logistic regression with multiple imputations of outcome status produced 
similar results (Appendix Table 1.1). 
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Table 1.3  Characteristics associated with death among 910 patients who initiated 
ART in Haiti in 2003-2004 using Cox Proportional Hazard Modeling.
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Characteristics of the 10-Year Survivors: 
The median age of survivors was 49 years (IQR 43-55).  Median body weight 
increased by 2 kilograms for men (from 58 to 60kg) and by 9 kg for women (from 51 
to 60 kg) from time of ART initiation to 10 years.  Median CD4 count increased from 
146 cells/uL (IQR 62-214) at time of ART initiation to 541 cells/uL (IQR 355-762) at 
10 years.  Over two-thirds of patients (73%) remained on first-line regimens over the 
10-year period.  The median time to switch among those on second-line was 
approximately 6 years (75 months (IQR 46-106).  Over a third of survivors (36%) had 
documented evidence of a chronic non-communicable disease, most often 
cardiovascular disease (109), lung disease (67), and diabetes (2).  Four patients had 
more than one diagnosis.   
DISCUSSION 
This analysis documents the 10-year survival of the first cohort of adult and adolescent 
patients to receive ART in a public HIV program in Haiti to be 63-71%.  Such high 
survival is impressive given a large proportion of the cohort had advanced AIDS at 
time of ART initiation and the continuous political, socioeconomic and natural 
catastrophes that occurred in Haiti during the 10-year study period.  These results 
demonstrate the long-term sustainability of international efforts to provide ART in 
resource-poor settings and the effectiveness of ART on patient outcomes.       
Ten-year survival of ART cohorts from resource-poor settings remain 
uncertain.  Three-year retention after ART initiation has been reported to be 64% in 
Latin America and the Caribbean, 65% in Africa, and 80% in Asia in a recent 
systematic review of 154 cohorts from 42 low- and middle-income countries (32). In 
this same review, estimated retention across all sites using lifetime table analysis was 
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60% at 5 years.   Long-term survival of our cohort appears similar to the early ART 
era in the United States, defined as 1997-1999, which report annual death rates of 
2.8% to 4.1% (33).  Our cohort’s 10-year survival estimates of approximately 70% 
illustrate what is possible in resource-poor settings.  
The high mortality seen in the 6 months immediately after ART initiation is 
similar to other studies (14, 34-39) and in part reflects the high burden of opportunistic 
infections (10, 14-17).  The early mortality in this cohort is similar to early mortality 
rates from other ART programs in resource-poor settings (14, 34-38).  A meta-
analyses of one-year mortality was 6.4% (95% CI 5.1%-7.7%) across 18 ART 
programs in Africa, Asia, and South America and 8.3% (95% CI 7.6% -9.1%) from 7 
sites in Latin America and the Caribbean (40) (41).  In these programs, the proportion 
of patients who were categorized as LTF was greater than those with documented 
death.  Given a non-trivial proportion of the patients who are categorized as LTF 
represent undocumented death (42, 43), corrected death rates from these programs are 
much higher.  Interestingly, there does not appear to be an increase in the rate of death 
or LTF in our cohort during 2010 and 2011, post-earthquake.   
Characteristics associated with early death in this cohort are consistent with 
those in the literature including male sex, older age, advanced WHO stage, low 
weight, and tuberculosis (34, 39, 44-49).  Like other cohorts, advanced age remains an 
independent risk factor for early and late death, and may underscore data suggesting 
younger age favors CD4+ cell restoration on ART (48, 50, 51).  Characteristics 
associated death after 6 months to 10 years shift from biomedical characteristics to 
demographic and behavioral characteristics.  Specifically, extreme poverty of earning 
less than $1 per day and lowest quartile adherence became significant predictors.   
  18 
    
A striking characteristic of the survivors is the fact that 73% remain on first-
line therapy after 10 years.  In a prior study from Haiti, patients who failed first-line 
therapy based on clinical and/or immunologic criteria and did not switch to second-
line therapy faced a higher mortality than those who switched after failure (52). 
Perhaps, one reason we are seeing such high proportion of first-line therapy among the 
10-year survivors is that patients who failed first-line died prior to switching to 
second-line. New initiatives to monitor viral load annually among ART patients may 
identify patients earlier who qualify for second-line therapy and further improve 
survival. 
Increasing prevalence of chronic non-communicable diseases (NCDs) among 
populations on long-term ART is well documented and is due to a convergence of 
factors from the virus, treatment side-effects, and host responses leading to metabolic 
abnormalities (53, 54). The prevalence of NCDs among survivors (38%) may differ 
from cohorts who initiate treatment at higher CD4 counts in the past several years.  
Cardiovascular and lung diseases have been associated with low CD4 counts (55-59) 
and our cohort had very low CD4 counts at ART initiation when ART eligibility was 
based on a CD4+ count < 200 cells/uL.  Additionally, zidovudine— for which 89% of 
patients were using for first-line treatment— and stavudine are associated with 
metabolic diseases after adjustment for risk factors for diabetes and lipids (60), and 
current first-line regimens do not include these medications.  The prevalence of NCDs 
among survivors in this cohort draws attention to importance of NCD diagnoses and 
management among persons living with HIV in resource-poor settings (61).  Providers 
of HIV care among aging HIV populations will need to be trained in NCD 
management and integrated models of HIV-NCD care need to be implemented. 
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Strengths of this analysis include it is one of the first large cohorts of patients 
to initiate ART in a resource-poor setting, and reports 10-year survival.  The inclusion 
of multiple methods to estimate and compare survival and that fact that only 12% of 
patients were lost over the 10-year period provides confidence around the survival 
estimate.   
CONCLUSION 
The 10-year survival of patients with AIDS receiving ART in Haiti is approximately 
70%, which demonstrates the long-term sustainability of international efforts to 
provide ART in resource-poor settings.  These results attest to the collaboration of 
international donors and the Haitian Ministry of Health, the dedication of Haitian 
clinic staff, and the perseverance of patients all of which have transformed HIV into a 
chronic manageable disease.  
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APPENDIX 1 
 
Appendix Table 1.1 Predictors of survival at 6 months and 10 years using logistic 
regression model and survival estimated by multiple imputation methods. 
 
Predictors of 6-month mortality OR P Value 
Advanced stage 
(WHO III or IV) 
3.2 <0.001 
Tuberculosis 
(present at baseline) 
1.9 0.04 
Weight  
(for every -10kg difference from 
median weight for gender) 
1.5 0.002 
CD4+  
(for every lnCD4 difference of 0.7 = 
difference between 200 and 100, or 
100 and 50) 
1.2 0.007 
    Area under ROC curve = 0.75   
Predictors of 10-year mortality   
Adherence 
(for every -10 percentage point 
difference) 
1.8 <0.001 
Income < $1 per day 1.6 0.007 
Age 
(for every +15-year difference) 
1.6 <0.001 
Advanced stage 
(WHO III or IV) 
1.6 0.01 
Weight  
(for every -10kg difference from 
median weight for gender) 
1.3 0.004 
    Area under ROC curve = 0.80 
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CHAPTER TWO 
LESSONS LEARNED FROM THE TEN YEAR AIDS SURVIVORS AT GHESKIO  
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ABSTRACT 
 
Introduction:   The excellent 10-year survival of the first cohort of AIDS patient who 
initiated ART at GHESKIO are comparable to that observed in other countries in which 
ART has been initiated. However, given Haiti’s unique and fragile political and 
economic infrastructure these result deserve special attention. While few studies detail 
the experiences of those who have experienced long-term survival after starting ART, 
this study provides a unique opportunity to understand the psychosocial and contextual 
factors that enable patients living with HIV/AID to survive at least 10 years at 
GHESKIO after the initiation of ART.     
 
Methods: Individual audiotaped in-depth interviews that lasted 45 to 60 minutes, using 
a semi-structured open-ended format were conducted with 25 participants in between 
January 2015 and August 2015, who survived at least 10 years with AIDS. Grounded 
theory approach was used for data collection and analysis of this study.  Each has then 
transcribed verbatim and back-translated from Creole to English. Questions focused 
understanding how they survived in the midst of challenges faced by the 10 year 
survivors since starting ART, coping strategies used to overcome those challenges, 
accomplishments that they made during those ten years, and their hopes.    
 
Results: We integrated our core finding into an explanatory framework. Participants 
described stressors which is not only HIV but also poverty, sociopolitical challenges 
and stigmatization that are counterbalanced with positive outlook and the fact of having 
a goal. Psychosocial factors like caring for one’s child, spirituality and faith, the role of 
providers and adherence to antiretroviral helped them to look past the disease and have 
another meaning to theirs lives in order to survive the 10 years of ART        
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Conclusion: Aside the devastating health impacts of HIV itself, there was an underlying 
current of resilience, hope, and the desire to live.  The large proportion of women who 
have low education in Haiti does not necessarily equate with a lack of goals. As 
described in this study, women with children wanted to work and support their 
children’s education. This study provides a portrait of Haiti that is not defined by death 
or hopelessness.     
INTRODUCTION 
Among Caribbean countries, Haiti is known to have one of highest prevalence 
rates of HIV.1,2  In the early 1990s, prevalence rates peaked at 9% in some parts of the 
country.  The compounding effects of abject poverty, limited educational 
opportunities, high unemployment rates, and several devastating natural disasters 
cannot be discounted. However, over the past decade, a dramatic shift was observed in 
HIV trends. This downward trend has been attributed to concerted and strategic efforts 
of the local health ministry, community-based organizations, faith-based organizations 
and NGOs such as the Haitian Study Group on Kaposi’s Sarcoma and Opportunistic 
Infections (GHESKIO).4,5 GHESKIO, formed in 1982 by a group of Haitian health 
professionals, integrates HIV care with education on sexually transmitted infections, 
nutritional support, and economic development.6  Research is also a core component 
of GHESKIO’s mission.7    
In 2003, GHESKIO initiated clinical trials of ART treatment which 
subsequently became standard of care that was rendered free-of-charge to all patients 
with AIDS.  The advent of ART therapy in Haiti ushered in a new era of HIV 
treatment with unprecedented rates of survival. Prior to the initiation of ART, the one 
year survival was 30% which, improved almost 3-fold after the initiation of ART. The 
one-year survival rate among 910 adults and adolescent ART-naive patients who were 
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consecutively treated with ART from March 2003 to May 2004 was found to be 87%. 
8 Ten-year survival for this cohort was approximately 60% to 70%.9    While these 
rates are comparable to that observed in other countries in which ART has been 
initiated, the rates in Haiti deserve special attention given Haiti’s unique and fragile 
political and economic infrastructure. These rates of survival must be viewed in the 
context of the limited access to care, food insecurity, and tenuous housing. Surviving 
HIV under these conditions is a feat that is understated. Yet, much of the focus on 
HIV in Haiti remains on the staggering death rates.  While this is understandable, the 
new trends in HIV outcomes also calls for a focus on the factors which enabled 
individuals to survive 10 years are unknown.   
With few exceptions, the number of studies detailing the experiences of those 
who have experienced long-term survival after starting ART is limited.10  Survival in 
the midst of political unrest, economic turmoil, and one of the most devastating 
earthquakes in the western hemisphere points to the resilience of the Haitian 
population.  This study provides a unique opportunity to understand the psychosocial 
and contextual factors that enable patients living with HIV/AID to survive at least 10 
years at GHESKIO after the initiation of ART. The study was conducted in Creole and 
therefore, provides lessons on cross-language approaches to conducting qualitative 
research.  Understanding lived experiences of long-term survivors can be invaluable in 
developing interventions that are more responsive to the needs of patients.   
 
METHODS 
This qualitative study is nested within a larger study looking at cumulative 
incidence of survival at 10 years.  The methods to ascertain survival have been 
described above and elsewhere in the literature.9 Of the 910 Patients who initiated 
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antiretroviral therapy from 2003 through 2004 at GHESKIO, 482 patients (53%) were 
alive, 246 (27%) were deceased, 111 (12%) were lost to follow-up, and 71 (8%) had 
transferred to another clinic.  This subsequent qualitative study is a follow up of 16 
patients from this surviving cohort and nine 10-year survivors form a bigger 10-year 
survivor cohort.      
Participants were patients who received care at GHESKIO. Given the 
stigmatization associated with HIV, this study utilized an exhaustive informed consent 
process that has been developed by researchers at GHESKIO.  Careful steps were 
taken to ensure that all participants understood the rationale for the study and 
understood the reason for their participation. Participants were asked to complete a 
questionnaire detailing information about the study as a means of assuring the 
participants understood the objectives of the study and their role in the study. This 
process was conducted by social workers and field workers at GHESKIO. 
 
Data Collection:  
Grounded theory approach was used for data collection and analysis of this study. 
Grounded theory is an iterative process and evolving theory in the context of existing 
data until no new findings emerge (Charmaz, 2001). Individual in-depth interviews 
using a semi-structured open-ended format were conducted with participants between 
January 2015 and August 2015. All the interviews were conducted by the investigator 
in a private office at the GHESKIO. Interviews lasted about 45 to 60 minutes and each 
was audio-taped then transcribed verbatim. Questions focused understanding how they 
survived in the midst of challenges faced by the 10-year survivors since starting ART, 
coping strategies used to overcome those challenges, accomplishments that they made 
during those 10 years, and their hopes. 
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The interviews were all conducted by investigators who have received formal 
training in qualitative research as part of a Master of Science in Clinical Epidemiology 
and Health Services Research program. The training involved 6 weeks of didactic 
course work on the history and basic tenets of qualitative research as well as course 
work in qualitative data analysis. In addition, interviewers had opportunity to practice 
qualitative interviewing skills through role play with other students in the class. 
Additionally, guidance for the study design and interviews was provided by the senior 
author who is an expert in socio-behavioral research with more than a decade of 
experience performing qualitative research. The study was reviewed by GHESKIO 
IRB and the Cornell University IRB which approved the study. All study participants 
have provided written informed consent.  
   
Data Analysis: 
Grounded theory was used as the mean of understanding how the AIDS patients 
survived the 10 years of ART-1.  Data analysis occurred concurrently with data 
collection. Each interview was analyzed separately and as new questions arose about 
the underlying meaning of responses, new questions were added to further probes 
participants. As an example, initial interviews pointed to the salience of spirituality in 
the lives of participants. Therefore, new items were developed to further explore the 
role of spirituality and how it enabled survival. Additional probes included, “tell me 
about the role that church has play in your health," and "how has this supported or 
hindered you to remain healthy.”  When respondents explicitly mentioned God, this 
was further probed with questions such as, “tell me more about how God has impacted 
your health."  
As an inductive analytic approach, grounded theory involves constant 
comparison of data through a series of  iterative steps to develop an inductively 
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derived theory from the data11,12.  These steps involve include the identification of 
codes, concepts, categories and then theories to that describe the social phenomena of 
interest  13. Codes are descriptive labels or tags that represent key concepts that are 
being conveyed in the data. Codes can be actual responses or in vivo codes, select 
words from the transcripts, or words that represent key concepts.  The codes were then 
grouped into categories.  Categories were then analyzed to identify recurring and 
dominant themes. This process is iterative and involves exploring new evolving data 
in the context of existing data until no new findings emerge.  Detailed notes were 
maintained on the transcriptions, thus creating and ‘audit trial’ allowing for two 
separate and independent analyses of data.  These data underwent two rounds of 
independent analysis or coding to insure trustworthiness.  
Unique to this study was its cross-language and cross cultural focus.  The 
primary language of participants and the study principal investigator was Creole. 
Creole has many idioms and nuances that may confer certain meanings that when 
translated to English, may lose the underlying meaning.  Maintaining the meaning of 
responses as close as possible to what the participants intended is a core principle of 
qualitative research. 14 
 The procedures for data analysis were done in both Creole and English 
following recommendation from the literature reviews.  15  All interviews were 
conducted by bilingual qualitative researchers in Creole the primary language of the 
participants. The first stage involved translating the Creole text into English. Content 
analysis coding, development of categories and themes were done in Creole and 
English independently by two bilingual qualitative researchers each independently 
deriving  codes, categories, and themes in Creole and English.   The Creole codes, 
categories, and themes were translated from Creole to English and back translated to 
Creole.  The results of both Creole and English analysis were compared. When there 
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was a discrepancy the original transcripts in Creole were reviewed until consensus was 
derived. The final results were reviewed by a panel of investigators who were 
clinicians at GHESKIO and thus were familiar with the care of patients living with 
HIV.  This panel also included bilingual researchers with expertise in qualitative 
research.  
 
RESULTS 
Data saturation was reached at 25 participants. 64% were women which represents the 
feminization of HIV in Haiti.  The length of time on antiretroviral treatment ranged 
from 10 to 12 years. Interviews resulted in 681 codes have been grouped into 6 
categories that best illustrate factors that enabled them to survive.  The most 
frequently cited categories that illustrated factors that enabled participants to survive 
was the role of providers, the role of spirituality and their faith,  the role of caring for 
children, having a goal, having a positive outlook, and medication adherence.   
 
The Role of Providers: 
“Then someone told me to come here. They told me that they will take good care of me 
here. They also told me they will not give me the medications all of the sudden without 
being tested. Then when I came to do the test they told me that I tested positive for 
HIV” 
“Since I started to come here, everybody here has become my friend. I come 
here because everyone in the staff is my friend, because of my familiarity with my 
doctors, my familiarity with my nurses.  
 “My friend, I can tell you if Doctors did not exist, the country itself would 
disappear. I can say that the doctors come right after GOD” 
  37 
    
Spirituality:  
A major recurring category was that of spirituality and faith in God. God was viewed 
as a confidante, friend, and healer. Having God to confide in was essential for some 
participants who felt that they were unable to disclose their status to anyone else. 
 “My problem is that I was stressed because I could not find a person who 
could understand me to share this with. And I realized that if I tell someone about my 
status that person will share it with others. Then I said to God that everything is in 
your in hands, please take over, don’t let me get stressed too much”  
 “I hope that God will make the cure available, as the treatment is now 
available to improve our health. Then God does his job, to make the cure available to 
us in order to keep living”  
 “The same way he let the disease enter my body; if he wants he can make it 
disappear. If he wants to let you suffer because of your sin he can let this happen, but 
since he is different from us he can treat us as well”   
Belonging to a church reinforced the role of spirituality that the participant 
described. The church provided social support.  
“I have been to church more than when I did not know I was infected. I have 
noticed that God deserves more glory because I was already in the tomb and he has 
withdrawn me. It is like your father that told you not to do something you do it and he 
still loves you and forgets you. So you have to be ashamed about your attitude and 
change! So I have to become wiser and more obedient towards God! ” 
 “Even if I do not go to church I have to pray, but when you go to church and 
you have a place where you are praising the Lord it is better and you can even find 
prayer support. My prayer is too weak, I think if several people were praying God for 
my treatment I would have already found a solution.”  
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The Role of Providing for One’s Child: 
Approximately 60% of the participants were women and many had young children at 
their time of diagnosis. Having children and supporting their children was another 
factor which enabled some to survive.  
 “Well (my kids), that’s a great accomplishment for me, because I didn’t expect 
that. The reason I didn’t expect it.  Because when you are working to pay school 
tuition for your child and the child really understand what you’re doing for him, he 
understand the importance of education and completed high school, that is a great 
accomplishment for his parents”  
 “The thing that I’m proud of is the fact of my daughter goes to university now. 
I prayed God for that. I want her to be married before my death. I want God to keep 
me alive for that”  
 “I just wanted to live, because I didn’t want to die letting my children. Who 
would take care of them? I don’t know. They wouldn’t be educated. ” 
 
Having a Goal:  
Having a goal for economic development was also a crucial factor. For some 
participants, it was a process of acquiring skills for a profession in order to have an 
income that was empowering. 
“I compare myself like other because I am doing all my activities. There is no 
difference between us. I only know that I am living with the virus but that does not 
mean that I am sick. I can say that I am like any other young person. Everything that 
they can do I can do it also” 
“I am an educator, I inform the youth, I accompany them, and I show them 
that they are not alone.  I work alongside them, and I support them”  
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“If for some reason I cannot do the laundry then I try to sell a few things out of 
my store. Also sewing is one of my daily activities as usual. I respect my dignity as 
long as I find something to do I will always try my hardest”   
“For me, I want to complete my secondary studies, find a scholarship and to 
go study medicine, and become a pediatrician”  
 
Positive Coping and Stress Reduction: 
Another important aspect of survival was finding a way to cope with stress for dealing 
with HIV.  
“Sometimes I give them jokes. I resigned on myself by giving jokes. That is 
how I confront life, in order to prevent stress getting me down” 
  “The most important thing consists in living with the disease like you used to 
live before you knew you were infected. Even if people are criticizing you, act as if 
nothing happened.” 
 “Sometime, I don’t even talk about the disease. I remember that I’m sick only 
when I come here.” 
 “I was born with the disease and I know that everybody has their cross to lift 
in life. And I sometime say if I was not infected and I was handicapped or blind or if I 
had cancer and If I had to choose I would prefer being infected by the virus, because I 
can lift this cross but the other ones would be too heavy for me, when I imagine a 
person who is born but who cannot ever walk I consider Aids like a blessing compared 
to those diseases” 
 
Attitudes Towards Medication Adherence: 
Having a positive attitude toward medication adherence was also described as an 
essential aspect of living with HIV. 
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 “I take my medicine as if I was taking vitamins. I just take the paper in which I 
have the medicine and I take it. I may hide the bottle to avoid people of reading what 
is written on the bottle. But I don’t mind to just buy water and take my pills, I don’t 
care.” “I know I cannot spend one day without brushing my teeth so I have to do the 
same when it comes to taking the medicine, it is a must for me like brushing my teeth” 
  “When I do not take the medicine, I feel upset, nervous, stressed, I feel I have 
one day missing in my life. The medicine becomes a drug for me. I mean I cannot do 
anything without it.”  
 
Theory: 
In order to survive, one had to look past the disease and have another meaning to their 
lives. The concept is outlined in Figure 2.1. 
 
Figure 2.1 Elements of resilience of the ten year AIDS survivors at GHESKIO 
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DISCUSSION  
The impact of HIV on the lives of Haitian patients is well-known.  However, 
what is less known, is how patients have been able to survive a disease that has been 
until recent decades, invariably fatal.  This paper is a paradigm shift in the approach to 
studying HIV. The premise of this paper is that understanding factors that enable 
survival is important to developing sustainable programs.  
This qualitative study identified 6 factors: the role of providers, the role of 
spirituality and their faith, the role of caring for children, having a goal, having a 
positive outlook, and medication adherence.   The underlying theme was having 
something to live for and something to sustain life. There are prior reports by Severe 
et al. of the resilience of the people of Haiti that pointed the will to survive in spite of 
their circumstances.  For many participants in this study factors such as spirituality 
and one’s child took precedence over the disease.  These factors enabled patients to 
transcend their reality and thus, survive.    
 An overarching theory that can best describe this phenomenon of survival was 
that one had to look past the disease and have another meaning in life.  As an example, 
faith provided a sense of hope and healing that surpassed participants' realities.  
Having children who needed to be reared and educated enabled patients to transcend 
their current circumstances and live towards a goal of providing for children. Having 
personal goals, such as the desire to work, enabled patients to live beyond their 
circumstances and seeming overcome the despair of HIV. Having support from 
providers and other family also enabled patients to survive and reinforced their reason 
for living.  Even their attitude toward taking medications was seemed to defy their 
circumstances.   Patients described taking medications like vitamins or routine as 
brushing one’s teeth.  
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 Although there were descriptions of the devastating health impacts of HIV 
itself, there was an underlying current of resilience, hope, and the desire to live. This 
study has limitations in that it was done among patient from one practice site and there 
was a preponderance of women. However, reflects the reality that few clinical sites are 
able to provide care and support research like GHESKIO. This study also reflects the 
feminization of HIV in Haiti.  The sample size of 25 is consistent with prior 
qualitative studies.   Additionally, it is not known whether those who survived and 
those who did not had different outlooks. One can only conclude that these results are 
illustrations of what some participants who survived described. Comparison with those 
who did not survive cannot be made.  
 Qualitative studies provide an important adjunct to the traditional cohort 
studies or clinical trials. The cross-language approach provides guidance on future 
studies conducted in participants own language. This is critically important to 
preserving the essence of what participants are reporting and ensuring that the 
meaning is not lost in translation.  The success of GHESKIOs ART program 
demonstrates that rapid and wide-scale implementation of ART is feasible.  The 
findings from 910 patients provide rationale for replication of this program and the 
return on investment on supporting ART treatment in resource poor countries.  
Moreover, this study demonstrates the importance of developing supportive programs 
that help to build resilience and hope. The large proportion of women who have low 
education in Haiti does not necessarily equate with a lack of goals. As described in 
this study, women with children wanted to work and support of their children’s 
education.  Women voiced their desire in working any job type, such as doing laundry.  
 This study provides a portrait of Haiti that is not defined by death or 
hopelessness.  Understanding the concept of survival among this population can help 
to advance studies from mortality to survival and quality of life.   
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